Financial Performance - Revenues increased 44% year-over-year from $34.3 million in Q3 2023 to $49.3 million in Q3 2024[1] - GAAP net loss narrowed to $(4.2) million compared to $(4.4) million in Q3 2023[3] - Adjusted EBITDA for Q3 2024 was $8.8 million, down from $9.2 million in Q3 2023[3] - For Q3 2024, Harrow reported a GAAP net loss of $4,220,000, an improvement from a net loss of $4,391,000 in Q3 2023[14] - Adjusted EBITDA for Q3 2024 was $8,808,000, down from $9,209,000 in Q3 2023, reflecting a decrease of approximately 4.4%[14] - For the nine months ended September 30, 2024, the GAAP net loss was $24,258,000, compared to a net loss of $15,263,000 for the same period in 2023[14] - Basic and diluted loss per share for Q3 2024 was $(0.12), compared to $(0.13) in Q3 2023[16][18] Operational Metrics - Total prescriptions for VEVYE increased by 55% over Q2 2024[1] - Customer unit demand for IHEEZO® rose by 15% compared to Q2 2024[1] - Core gross margin improved to 80% in Q3 2024 from 78% in Q3 2023[3] - Gross profit for Q3 2024 was $37,239,000, with a gross margin of 76%, compared to a gross profit of $24,198,000 and a margin of 71% in Q3 2023[16][18] - Core results for the nine months ended September 30, 2024, showed a gross profit of $104,144,000, with a gross margin of 78%[17] Cash and Liabilities - Cash and cash equivalents stood at $72.6 million as of September 30, 2024, down from $74.1 million at the end of 2023[8] - Current liabilities increased significantly to $95.0 million from $49.3 million at the end of 2023[8] Future Outlook - The company expects meaningful overperformance in Q4 2024 revenue guidance due to positive demand trends[1] - The company is expanding access and affordability through multiple new partnerships[1] Expenses - The company incurred stock-based compensation and expenses of $4,385,000 in Q3 2024, slightly down from $4,476,000 in Q3 2023[14] - Operating income for Q3 2024 was $1,321,000, compared to an operating income of $1,744,000 in Q3 2023[16][18] Investment Loss - The company reported an investment loss of $3,171,000 for the nine months ended September 30, 2024, compared to an investment loss of $2,676,000 for the same period in 2023[14][19] Core Results - Harrow's core results exclude certain amortization and impairment charges, with core net loss reflecting adjustments for exceptional items[15]

Core Insights - Harrow (HROW) reported a quarterly loss of $0.12 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.05, marking an earnings surprise of -140% [1] - The company generated revenues of $49.26 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 11.42%, but showing an increase from $34.27 million year-over-year [2] - Harrow's stock has increased by approximately 345.6% since the beginning of the year, significantly outperforming the S&P 500's gain of 25.5% [3] Company Performance - Over the last four quarters, Harrow has surpassed consensus EPS estimates only once [2] - The current consensus EPS estimate for the upcoming quarter is $0.50 on revenues of $81.8 million, and for the current fiscal year, it is $0.09 on revenues of $223.66 million [7] - The estimate revisions trend for Harrow is currently favorable, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Drugs industry, to which Harrow belongs, is currently ranked in the top 25% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Core Viewpoint - The article emphasizes the importance of confirming the sustainability of a trend in short-term investing, highlighting that successful entry timing is crucial for capitalizing on price movements [1][2]. Group 1: Trend Analysis - The trend can reverse before exiting a trade, potentially leading to short-term capital losses for investors, necessitating confirmation of sound fundamentals and positive earnings estimates to maintain stock momentum [2]. - A unique short-term trading strategy, referred to as the "Recent Price Strength" screen, helps identify stocks with sufficient fundamental strength to sustain their recent uptrends [3]. Group 2: Stock Example - Harrow (HROW) - Harrow (HROW) has shown a solid price increase of 28.2% over the past 12 weeks, indicating investor confidence in its potential upside [4]. - HROW has maintained a price increase of 0.5% over the past four weeks, suggesting that the upward trend is still intact [5]. - Currently, HROW is trading at 82% of its 52-week high-low range, indicating a potential breakout opportunity [6]. Group 3: Fundamental Strength - HROW holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, which are critical for near-term price movements [6]. - The stock also has an Average Broker Recommendation of 1 (Strong Buy), reflecting high optimism from the brokerage community regarding its near-term price performance [7]. Group 4: Additional Opportunities - Besides HROW, there are several other stocks that meet the criteria of the "Recent Price Strength" screen, suggesting potential investment opportunities [8]. - The article encourages exploring over 45 Zacks Premium Screens tailored to different investing styles to identify winning stock picks [8].

The market expects Harrow (HROW) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on November 13, 2024, might help the stock move higher if these key numbers are ...

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, November 6th:Harrow, Inc. (HROW) : This eyecare pharmaceutical company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 164.3% over the last 60 days.Harrow’s shares gained 108.4% over the last three months compared with the S&P 500’s advance of 11.1%. The company possesses a Momentum Score  of B.Orla Mining Ltd. (ORLA) : This mining company has a Zac ...

Investors might want to bet on Harrow (HROW) , as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change. A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years. The power of a c ...

Shares of Harrow (HROW) have gained 5% over the past four weeks to close the last trading session at $47.20, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $59.45 indicates a potential upside of 26%.The mean estimate comprises four short-term price targets with a standard deviation of $12.23. While the lowest estimate of $44.80 indicates a 5.1% decline from the current price le ...

Core Viewpoint - The article emphasizes the importance of identifying and maintaining trends in short-term investing, highlighting the utility of a "Recent Price Strength" screen to find stocks with strong fundamentals that can sustain upward momentum [1]. Group 1: Stock Performance - Harrow (HROW) has shown a significant price increase of 133.3% over the past 12 weeks, indicating strong investor interest [2]. - The stock has also maintained a price increase of 27% over the last four weeks, suggesting that the upward trend is still intact [2]. - HROW is currently trading at 94.6% of its 52-week high-low range, indicating a potential breakout [2]. Group 2: Fundamental Strength - HROW carries a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises [3]. - The Zacks Rank system has a strong historical performance, with Rank 1 stocks averaging an annual return of +25% since 1988 [3]. - The Average Broker Recommendation for HROW is 1 (Strong Buy), reflecting high optimism from the brokerage community regarding its near-term price performance [3]. Group 3: Investment Strategy - The article suggests that HROW is not the only stock that meets the criteria of the "Recent Price Strength" screen, encouraging investors to explore other stocks that fit this profile [4]. - The article also mentions the availability of over 45 Zacks Premium Screens tailored to different investing styles, which can help identify potential winning stocks [4]. - The Zacks Research Wizard tool allows investors to backtest stock-picking strategies, enhancing the likelihood of successful investments [4].

Harrow (HROW) shares soared 8.4% in the last trading session to close at $49.75. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 16.8% gain over the past four weeks. Earlier this week, the company relaunched its ophthalmology drug, Triesence, which is approved for visualization during vitrectomy and for the treatment of ocular inflammatory conditions that are unresponsive to topical corticosteroids. This might have driven the sha ...

Stock Performance - Harrow Inc (HROW) shares increased by 3.26% during mid-day trading on October 2, reaching an intraday high of $46.10 before closing at $45.90, up from the previous close of $44.45 [1] - The current stock price is 3.47% below its 52-week high of $47.55 and 503.95% above its 52-week low of $7.60 [1] - Trading volume was recorded at 127,229 shares, which is 19.9% of the average daily volume of 640,221 shares [1] Analyst Forecasts - The average one-year price target for Harrow Inc (HROW) is $46.20, with a high estimate of $50.00 and a low estimate of $44.80, indicating a potential upside of 0.65% from the current price of $45.90 [2] - The consensus recommendation from four brokerage firms gives Harrow Inc an average rating of 1.8, suggesting an "Outperform" status on a scale where 1 is Strong Buy and 5 is Sell [2] - GuruFocus estimates the GF Value for Harrow Inc in one year to be $27.70, indicating a potential downside of 39.65% from the current price of $45.90 [2]